U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07089706) titled 'A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations' on July 21.
Brief Summary: The purpose of this study is to evaluate the immunogenicity and safety of variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE(R)) within the current epidemiological environment.
Study Start Date: July 21
Study Type: INTERVENTIONAL
Condition:
COVID-19
Intervention:
BIOLOGICAL: mRNA-1283 Variant-containing Formulation
Sterile liquid for injection
Recruitment Status: RECRUITING
Sponsor: ModernaTX, Inc.
Published by HT Digital Content Services with permission from Health Daily...